CN1163509C — 刺激神经和肾生长的RET配体(RetL)
Assigned to Bayogen Idec Massachusetts Inc · Expires 2004-08-25 · 22y expired
What this patent protects
本发明涉及编码Ret配体(RetL9)的核苷酸序列以及通过用RetLDNA或蛋白处理细胞和哺乳动物受治疗者以刺激神经和肾的生长的方法。本发明提供了分离纯化的编码RetL的DNA分子,含有任何RetL的核苷酸序列,特别包括鼠retL1 cDNA(SEQ ID NO:1),人部分RetL1cDNA(SEQ ID NO:8),人全长retL1 cDNA(SEQ ID NO:10),人retL2cDNA(SEQID NO:12),鼠retL3 cDNA(SEQ ID NO:12)或人retL3cDNA(SEQ ID NO:16),人部分retL3 cDNA(SE…
USPTO Abstract
本发明涉及编码Ret配体(RetL9)的核苷酸序列以及通过用RetLDNA或蛋白处理细胞和哺乳动物受治疗者以刺激神经和肾的生长的方法。本发明提供了分离纯化的编码RetL的DNA分子,含有任何RetL的核苷酸序列,特别包括鼠retL1 cDNA(SEQ ID NO:1),人部分RetL1cDNA(SEQ ID NO:8),人全长retL1 cDNA(SEQ ID NO:10),人retL2cDNA(SEQID NO:12),鼠retL3 cDNA(SEQ ID NO:12)或人retL3cDNA(SEQ ID NO:16),人部分retL3 cDNA(SEQ ID NO:18)或人retL3 cDNA (SEQ ID NO:20)。本发明进一步提供了RetL蛋白,具有包括大鼠RetL1(SEQ ID NO:2),人部分RetL1(SEQ ID NO:9),人全长RetL(SEQ ID NO:11),人RetL2(SEQ ID NO:13),鼠RetL3(SEQ ID NO:17),人部分RetL3(SEQ ID NO:19)或人RetL3(SEQID NO:21)的氨基酸序列。
Drugs covered by this patent
- Retevmo (SELPERCATINIB) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.